Abstract
Background: AD, a common chronic skin condition, has substantial impact on health-related quality of life (HRQoL). Stringent regulatory endpoints of Investigator Global Assessment score 0/1 and 75% reduction in Eczema Area and Severity Index (EASI-75) capture the AD skin lesion component, without encompassing all clinical endpoints. More inclusive tools are often needed to assess clinically meaningful responses in AD patients. We assess the effect of 52-week dupilumab treatment on a composite endpoint incorporating improvement in AD signs (EASI-75), symptoms (Peak Pruritus Numerical Rating Scale[PP-NRS] score≤4), and HRQoL (Dermatology Life Quality Index[DLQI]≤5) in adult AD patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
